Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Polyglutamine disease: acetyltransferases awry.

Hughes RE.

Curr Biol. 2002 Feb 19;12(4):R141-3. Review.

PMID:
11864588
[PubMed - indexed for MEDLINE]
Free Article
2.

Altered protein acetylation in polyglutamine diseases.

Bodai L, Pallos J, Thompson LM, Marsh JL.

Curr Med Chem. 2003 Dec;10(23):2577-87. Review.

PMID:
14529472
[PubMed - indexed for MEDLINE]
3.

Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.

Butler R, Bates GP.

Nat Rev Neurosci. 2006 Oct;7(10):784-96. Review.

PMID:
16988654
[PubMed - indexed for MEDLINE]
4.

[Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].

Jiang H, Jia D, Tang B.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Feb;27(1):52-5. doi: 10.3760/cma.j.issn.1003-9406.2010.01.011. Review. Chinese.

PMID:
20140868
[PubMed - indexed for MEDLINE]
5.

[Molecular biology of polyglutamine diseases].

Owecki M, Kozubski W.

Postepy Hig Med Dosw. 2002;56(6):779-88. Review. Polish.

PMID:
12661407
[PubMed - indexed for MEDLINE]
6.

[Mechanisms of neurodegeneration in polyglutamine diseases].

Tsuji S.

Rinsho Shinkeigaku. 2003 Nov;43(11):901-2. Review. Japanese.

PMID:
15152498
[PubMed - indexed for MEDLINE]
7.

Regulating histone acetyltransferases and deacetylases.

Legube G, Trouche D.

EMBO Rep. 2003 Oct;4(10):944-7. Review.

PMID:
14528264
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.

Krainc D.

Arch Neurol. 2010 Apr;67(4):388-92. doi: 10.1001/archneurol.2010.40. Review.

PMID:
20385902
[PubMed - indexed for MEDLINE]
9.

Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.

Rouaux C, Loeffler JP, Boutillier AL.

Biochem Pharmacol. 2004 Sep 15;68(6):1157-64. Review.

PMID:
15313413
[PubMed - indexed for MEDLINE]
10.

Polyglutamine expansion neurodegenerative disease.

Fischbeck KH.

Brain Res Bull. 2001 Oct-Nov 1;56(3-4):161-3. Review.

PMID:
11719245
[PubMed - indexed for MEDLINE]
11.

Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.

Anne-Laurence B, Caroline R, Irina P, Jean-Philippe L.

Subcell Biochem. 2007;41:263-93. Review.

PMID:
17484132
[PubMed - indexed for MEDLINE]
12.

Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.

Ross CA.

Neuron. 2002 Aug 29;35(5):819-22. Review.

PMID:
12372277
[PubMed - indexed for MEDLINE]
Free Article
13.

Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).

Sadri-Vakili G, Cha JH.

Curr Alzheimer Res. 2006 Sep;3(4):403-8. Review.

PMID:
17017871
[PubMed - indexed for MEDLINE]
14.

The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease.

Janknecht R.

Histol Histopathol. 2002 Apr;17(2):657-68. Review.

PMID:
11962765
[PubMed - indexed for MEDLINE]
15.

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

Expert Opin Investig Drugs. 2007 May;16(5):569-71. Review.

PMID:
17461732
[PubMed - indexed for MEDLINE]
16.

Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.

Langley B, Gensert JM, Beal MF, Ratan RR.

Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):41-50. Review.

PMID:
15723612
[PubMed - indexed for MEDLINE]
17.

[The advances in research on phosphorylation of polyglutamine disease].

Zhou YF, Jiang H, Tang JG, Tang BS.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Aug;25(4):414-7. Review. Chinese.

PMID:
18683139
[PubMed - indexed for MEDLINE]
18.

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.

Bauer PO, Nukina N.

J Neurochem. 2009 Sep;110(6):1737-65. doi: 10.1111/j.1471-4159.2009.06302.x. Epub 2009 Jul 23. Review.

PMID:
19650870
[PubMed - indexed for MEDLINE]
19.

Role of histone and transcription factor acetylation in diabetes pathogenesis.

Gray SG, De Meyts P.

Diabetes Metab Res Rev. 2005 Sep-Oct;21(5):416-33. Review.

PMID:
15906405
[PubMed - indexed for MEDLINE]
20.

Transglutaminase and diseases of the central nervous system.

Hoffner G, Djian P.

Front Biosci. 2005 Sep 1;10:3078-92. Review.

PMID:
15970562
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk